Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
Read More
Tag: SATT Paris-Saclay
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
